產品簡介

Clindamycin 是一種具有口服活性的廣譜抑菌林可酰胺類抗生素 (antibiotic)。Clindamycin 有效抑制細菌蛋白質合成，其具有以亞抑制濃度 (sub-MICs) 在金黃色葡萄球菌中毒力因子表達的能力。Clindamycin 的抗性是由 50S 核糖體亞基 (23S rRNA) 中抗生素結合位點的酶促甲基化產生。Clindamycin 降低殺白細胞毒素 (PVL)，毒性休克-葡萄球菌毒素 (TSST-1) 或 α-溶血素 (Hla) 的產生。Clindamycin 也可用于瘧疾的研究。

體外研究：

Clindamycin is a semisynthetic analogue of lincomycin. Clindamycin primarily inhibits the initiation of peptide chain synthesis by deregulating enzyme-catalyzed initiation of peptide bounds. Clindamycin appears to have a modest effect on protein synthesis by certain mammalian cells. Clindamycin is active against most gram-positive aerobic bacteria. Clindamycin is about eight times more active than lincomycin against Staphylococcus aureus and Streptococcus pneumonia. Clindamycin is four times more active than erythromycin against S. aureus and is active even against strains that are resistant to erythromycin, penicillin, and methicillin. Clindamycin is active against gram-positive anaerobes. Clindamycin highly activates against Bacteroides specie. Clindamyci also alters the bacterial surface in such a way that phagocytosis and intracellular killing of the bacteria is greatly facilitated. Clindamycin potentiates opsonization and phagocytosis.

體內研究：

Clindamycin (50 mg/kg daily administrated by intramuscular) increases the survival rate of monkeys infected with penicillin-resistant S. aureu to 87.5% (7/8). [5] Clindamycin (40 mg/kg administrated three times daily) protects 87.5% (7/8) of rabbits from anaerobic pulmonary infections induced by transtracheal inoculation of a mixture of B. fragillis, Streptococcus morbillorm, Fusobacterium nucleatum and Eubacterium lentum. Clindamycin (400 mg/kg treated by mixed in the diet) increases survival rate of mice infected with the Toxoplasma gondii to 100%, while all animals die in untreated group.

保存條件：-20°C

注意事項

1、為了您的安全和健康，請穿實驗服并戴一次性手套操作。